\
&
Contact us
\
&
Contact us
This was 7 months ago
LocationLiederhalle Stuttgart
The European Robotics Forum 2025 in Stuttgart, co-organized by euRobotics and Fraunhofer IPA, promises to be a dynamic intersection of innovation and collaboration in robotics and AI. Held at the renowned Liederhalle, the event will feature cutting-edge trends, foster meaningful partnerships, and offer exclusive visits to leading institutions like Fraunhofer Institutes, the University of Stuttgart, and Cyber Valley. With strong political support and an experienced team, ERF2025 aims to boost synergies and drive European advancements in robotics and AI.
The Cluster 4 NCP projects for digital and industrial topics, IDEAL-IST and NCP4Industry, are joint sponsors of this event and will have a booth at the exhibition area in Liederhalle advertising Horizon Europe calls, NCP services and the Cluster 4 NCP projects.
More information and registration available here.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Security Digital, Industry & Space Digital Europe Cybersecurity Defence
Research Infrastructures Culture and society Climate, Energy, Mobility
Digital, Industry & Space AI Continent Deployment: Best use of technologies
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
